Introducing RESI AI Panels

20 May

By Caitlin Dolegowski, Marketing Specialist, LSN

Caiti

Life Science Nation has released panel topics for its upcoming digital partnering conference: RESI AI, September 16-17. RESI AI panels host active investors who are joined by founders of portfolio companies to discuss funding, the early-stage landscape for AI companies in healthcare, and what makes a successful strategic partnership. Register by July 23 to save on super early bird rates.

There are many exciting advancements in this dynamic sector of life sciences, and we hope you’ll join us in highlighting the latest innovations, as well as take advantage of the powerful partnering system that has made RESI events a mainstay in early-stage fundraising.

If you’d like to be considered to join a RESI AI panel, please apply here.

The RESI AI panels will focus on the following topics:

Healthcare Communications

Bridging the Gaps between Patient and Provider

Communication between patients and providers is essential to health systems globally. AI-enabled technology addressing these needs and creating innovative solutions help patients better access and comprehend their options and care. Hear from early-stage founders connecting the healthcare system one relationship at a time.

Accelerated Pharmaceutical Development

Advancing and Optimizing Clinical Processes

AI is a necessary component of many aspects of the development of pharmaceuticals. However, the COVID-19 global pandemic has highlighted the need for rapid and reliable pharmaceutical advancement. Learn how researchers can utilize AI to optimize performance and save lives.

Reproductive Wellness

Highlighting Innovation and Broad Applications

Comprehensive reproductive care has a global impact on health and society. AI-assisted advancement in this field is critical to provide access to patients regardless of location, medical history, and socioeconomic status. Hear from leaders how their technology is creating equity in quality and excellence in care.

Diagnostic Wearables

Connecting Patients to Their Health

Wearable sensors are a fast-growing area of medical device and diagnostic technology. The function and accuracy of these devices are critical to patient care and communication. AI is a powerful tool equipping these to provide accurate results up to the moment and enabling users to make well-informed decisions on their health.

Healthcare Systems and Infrastructure

Creating Synergy for Efficient Patient Care

Optimized healthcare systems and digital infrastructure are paramount to the patient experience. From electronic health records to portal access and communications, AI-enabled medical centers are better equipped to help patients in the digital age. When it comes to healthcare, small synergistic changes create a big impact on the patient experience and contribute to better systems globally.

Precision Medicine

Fitting the AI Piece of the Puzzle

The AI impact on precision medicine is essential in targeting and treating genetic disorders, rare diseases, oncology, and more. It’s important that entrepreneurs learn how to navigate pitfalls such as market saturation, regulatory risk and guidelines, as well as how to better define patient populations, challenges and tackle manufacturing and commercialization.

A Match Made at RESI: Part I

20 May

By Rory McCann, Marketing Manager & Conference Producer, LSN

Michele Marzola is a prolific investor and entrepreneur in healthcare with a career that spans decades. He knows exceptional technology when he sees it and a powerful team when he meets them, so when he met Antoine Prestat, founder of PEP-Therapy at RESI March 2020, he knew he’d found something special.

In Part I of our two-part interview about Michele’s investment in PEP-Therapy, we discuss his process when sourcing assets, due diligence, digital partnering, and his best advice to fundraising entrepreneurs.

There’s still time to sign up for Digital RESI June! Register today to start booking meetings with over 350 investors.  

Hot Investor Mandate: Private Wealth Firm Opportunistic Within Life Science Sectors, Investing As Early as Discovery/Pre-Prototype Stage of Development

20 May

A private wealth investment firm provides strategic and operational support for the firm’s investment initiatives and entrepreneurial endeavors. The firm invests in early to late stage (seed to pre-IPO) companies worldwide.

The firm is agnostic across life science sectors, including platforms, therapeutics, devices and tools, and services and including discovery, early stage preclinical and clinical-stage opportunities, though open to commercial-stage or adjacent discovery/development technologies.

The firm seeks companies with founders who have a clear vision, highly differentiated technology, and desire to build a durable business.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Canada VC Firm Actively Seeks Therapeutics, Devices, Diagnostics Technologies in North America, Investing Up to $15M

20 May

A Canada-based venture capital firm focused exclusively on the life sciences industry is actively making seed and venture investments from their latest fund, and usually seeks to be the first institutional capital in a company. Equity investments are the preferred capital structure; however convertible notes may be employed for seed investments. Initial investments may be as small as $1M (seed-stage companies) with up to $15M allocated over the life of the investment. The firm prefers to lead financing rounds of Canadian companies and co-lead investments based in the United States.

The firm is focused on investments in therapeutics, medtech and diagnostics. The firm is agnostic in terms of subsector and indication and invests in early pre-clinical up unto Phase III therapeutic assets with the caveat being that the capital needs of the company fall within the fund’s criteria for investment size. As for devices and diagnostics stage of development, the firm invests in products in development and in clinical settings given the aforementioned capital constraints for therapeutics. For medtech, the firm has a preference for 510(k) regulatory pathways but will also evaluate devices with a PMA pathway.

The firm has no strict criteria for management teams and will work with novice entrepreneurs, however those management teams with experience are favored. The firm looks to originate 2/3 of its investments in Canada and the rest in the United States, and typically seeks a board seat along with investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC With Strong China Expertise Invests in Novel Therapeutics Across All Modalities, from Early to Growth Stage

20 May

A life science venture capital firm with strong China expertise and global capabilities founded in 2017, discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. The firm operates offices in USA and China.

The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services. The firm is looking to invest from seed, first institutional round, to growth stage.

The firm has no specific requirement for the company & management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: PE Firm Invests Up to €15M in Early-Stage Biotech and Medtech Companies in Europe

20 May

A private equity firm based in Europe typically makes an initial investment of up to €2-3M, and up to €10-15M over the life of the investment, which can be start as early as Series A. The firm invests in EU-based companies.

The firm’s venture team focuses its life sciences investments on therapeutics: mainly biotech companies and opportunistically in medtech companies developing therapeutic implantable devices. The firm is agnostic in terms of subsectors, indications and stage. Currently, the firm is active in many subsectors.

The firm seeks to acquire minority stakes in its portfolio companies. The firm is looking for companies with a talented and entrepreneurial management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Introducing RESI AI Panels

18 May

By Elizabeth Murphy, Manager of Business Development, LSN

It is with great pleasure that we announce the upcoming panel discussions for the RESI AI digital partnering conference, September 16-17. Register by July 23 to save on super early bird rates and save an additional $100 with code: MANDATE100.

Apply here for the chance to join one of the following panel discussions:

Healthcare Communications

Bridging the Gaps between Patient and Provider

Communication between patients and providers is essential to health systems globally. AI-enabled technology addressing these needs and creating innovative solutions help patients better access and comprehend their options and care. Hear from early-stage founders connecting the healthcare system one relationship at a time.

Accelerated Pharmaceutical Development

Advancing and Optimizing Clinical Processes

AI is a necessary component of many aspects of the development of pharmaceuticals. However, the COVID-19 global pandemic has highlighted the need for rapid and reliable pharmaceutical advancement. Learn how researchers can utilize AI to optimize performance and save lives.

Reproductive Wellness

Highlighting Innovation and Broad Applications

Comprehensive reproductive care has a global impact on health and society. AI-assisted advancement in this field is critical to provide access to patients regardless of location, medical history, and socioeconomic status. Hear from leaders how their technology is creating equity in quality and excellence in care.

Diagnostic Wearables

Connecting Patients to Their Health

Wearable sensors are a fast-growing area of medical device and diagnostic technology. The function and accuracy of these devices are critical to patient care and communication. AI is a powerful tool equipping these to provide accurate results up to the moment and enabling users to make well-informed decisions on their health.

Healthcare Systems and Infrastructure

Creating Synergy for Efficient Patient Care

Optimized healthcare systems and digital infrastructure are paramount to the patient experience. From electronic health records to portal access and communications, AI-enabled medical centers are better equipped to help patients in the digital age. When it comes to healthcare, small synergistic changes create a big impact on the patient experience and contribute to better systems globally.

Precision Medicine

Fitting the AI Piece of the Puzzle

The AI impact on precision medicine is essential in targeting and treating genetic disorders, rare diseases, oncology, and more. It’s important that entrepreneurs learn how to navigate pitfalls such as market saturation, regulatory risk and guidelines, as well as how to better define patient populations, and tackle manufacturing and commercialization challenges.

← Older Entries
Newer Entries →